Old drugs, new hope: imatinib combo tested for rare tumors
NCT ID NCT01046487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested two cancer drugs—imatinib mesylate and cyclophosphamide—given daily by mouth to 26 people with rare, advanced tumors that had no standard treatment. The main goal was to find the safest dose of imatinib when combined with a fixed dose of cyclophosphamide. Researchers also looked for any signs that the drugs could shrink or control the tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imatinib mesylate and cyclophosphamide
What this could lead to
If successful, this could point toward a new treatment option for people with rare, advanced cancers that have no standard therapy.
What could go wrong
This is an early Phase 1 trial with only 26 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Institut Bergonié
Bordeaux, 33076, France